

Liminatus Pharma shares surged 30.49% in after-hours trading following an amended InnocsAI merger deal that speeds up closing.
You can purchase shares of Liminatus Pharma (NASDAQ:LIMN) through any online brokerage.
Other companies in Liminatus Pharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
There is no analysis for Liminatus Pharma to provide a consensus price target.
The stock price for Liminatus Pharma (NASDAQ: LIMN) is $2.74 last updated November 6, 2026 at 7:19 AM EST.
There are no upcoming dividends for Liminatus Pharma.
Liminatus Pharma does not have any upcoming earnings scheduled.
There is no upcoming split for Liminatus Pharma.
Liminatus Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the...